Fresenius | FRE - Operating Expenses


Fresenius reported EUR5.25B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Akzo Nobel EUR 2.34B 206M Jun/2026
Alcon AG USD 2.41B 4M Mar/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BASF EUR 15.77B 1.16B Jun/2026
Bayer EUR 9.88B 452M Mar/2026
Beiersdorf EUR 4.16B 212M Dec/2025
DaVita Healthcare Partners USD -765.1M 9.6M Jun/2026
Demant DKK 9.63B 241M Dec/2025
E.ON EUR 17.71B 2.42B Mar/2026
Essilor EUR 12.52B 568M Jun/2026
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Getinge SEK 7.03B 2.96B Jun/2026
Givaudan CHF 3B 107M Dec/2025
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GN Store Nord DKK 2.16B 1.94B Mar/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Philips EUR 3.75B 147M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
RWE EUR 4.43B 644M Mar/2026
Sanofi EUR 9.92B 607M Jun/2026
Smith & Nephew USD 2.59B 71M Jun/2026